Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCX063 ocular exposure study in retinal detachment surgery
ACTRN12621001357842Phase 2Withdrawn
- Sponsor
- Certa Therapeutics
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of OCX-063 in retinal detachment (2 cohorts), sponsored by Certa Therapeutics. Primary endpoints: Levels of OCX063 in vitreous humour and Levels of OCX063 in aqueous humour. Planned start Dec 2021; status: withdrawn.
02
Drugs
OCX-063
03
Conditions
retinal detachment
Beyond the preview
Go deeper on ACTRN12621001357842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001357842.